- A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients. Annemans, L., Warie, H., Nechelput, M., Peraux, B. Acta Gastroenterol. Belg. (2004)
- Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Annemans, L., Moeremans, K., Lamotte, M., Garcia Conde, J., van den Berg, H., Myint, H., Pieters, R., Uyttebroeck, A. Support. Care. Cancer (2003)
- Modeling costs and cost-effectiveness of different CMV management strategies in liver transplant recipients as a support for current and future decision making. Annemans, L., Moeremans, K., Mutimer, D., Schneeberger, H., Milligan, D., Kubin, M. Value. Health (2002)
- Early modelling for assessing health and economic outcomes of drug therapy. Annemans, L., Genesté, B., Jolain, B. Value. Health (2000)